D. Boral Capital to Host KOL Webinar With World Leading Experts Featuring Insights & Breakthroughs from Enlivex's Knee Osteoarthritis Program
Enlivex Therapeutics (Nasdaq: ENLV) has announced an upcoming KOL webinar hosted by D. Boral Capital on September 30, 2025, at 10:00 AM ET. The webinar will focus on the company's knee osteoarthritis program and recent positive Phase IIa topline data from its Allocetra™ treatment.
The panel features distinguished experts including Professor Ali Mobasheri, Professor Philip Conaghan, Enlivex's Vice Chairman Dr. Roger Pomerantz, and D. Boral's Jason Kolbert. The data demonstrated significant improvements in pain reduction and function for moderate-to-severe knee osteoarthritis patients, addressing an unmet medical need in a large patient population with no currently approved disease-modifying therapies.
Enlivex Therapeutics (Nasdaq: ENLV) ha annunciato un prossimo KOL webinar organizzato da D. Boral Capital che si terrà il 30 settembre 2025 alle 10:00 ET. Il webinar si concentrerà sul programma di osteoartrosi del ginocchio dell’azienda e sui recenti dati positivi di fase IIa topline del trattamento Allocetra™.
Il panel vede esperti di spicco tra cui il professor Ali Mobasheri, il professor Philip Conaghan, il vicepresidente di Enlivex Dr. Roger Pomerantz e Jason Kolbert di D. Boral. I dati hanno mostrato miglioramenti significativi nella riduzione del dolore e nella funzione per pazienti con osteoartrite del ginocchio da moderata a grave, affrontando un bisogno medico non soddisfatto in una ampia popolazione di pazienti senza terapie modificanti la malattia attualmente approvate.
Enlivex Therapeutics (Nasdaq: ENLV) ha anunciado un próximo seminario web KOL organizado por D. Boral Capital que se celebrará el 30 de septiembre de 2025 a las 10:00 a. m. ET. El seminario se centrará en el programa de osteoartritis de rodilla de la empresa y en los recientes datos positivos de fase IIa topline del tratamiento Allocetra™.
El panel contará con distinguidos expertos, entre ellos el profesor Ali Mobasheri, el profesor Philip Conaghan, el vicepresidente de Enlivex Dr. Roger Pomerantz y Jason Kolbert de D. Boral. Los datos demostraron mejoras significativas en la reducción del dolor y en la función de pacientes con osteoartritis de rodilla de moderada a severa, abordando una necesidad médica no satisfecha en una amplia población de pacientes sin terapias modificadoras de la enfermedad actualmente aprobadas.
Enlivex Therapeutics (나스닥: ENLV)가 D. Boral Capital이 주최하는 다가오는 KOL 웨비나를 발표했으며 2025년 9월 30일 동부 표준시 10:00 AM에 개최됩니다. 이 웨비나는 회사의 무릎 골관절염 프로그램과 Allocetra™ 치료의 최근 긍정적인 2상 초두 데이터에 초점을 맞출 것입니다.
패널에는 아리 모바셰리 교수, 필립 코배인 교수, 엔리렉스의 부회장 Dr. Roger Pomerantz, D. Boral의 Jason Kolbert 등 저명한 전문가가 참여합니다. 데이터는 중등도에서 중증의 무릎 골관절염 환자에서 통증 감소와 기능 개선이 유의하게 나타났으며, 현재 승인된 질병의 진행을 변화시키는 치료법이 없는 대규모 환자군에서 충족되지 않은 의학적 필요를 해결합니다.
Enlivex Therapeutics (Nasdaq : ENLV) a annoncé un prochain webinaire KOL organisé par D. Boral Capital et prévu le 30 septembre 2025 à 10 h 00 ET. Le webinaire portera sur le programme d’arthrose du genou de l’entreprise et sur les récents données positives de la phase IIa en topline de son traitement Allocetra™.
Le panel réunira des experts distingués, dont le professeur Ali Mobasheri, le professeur Philip Conaghan, le vice-président d’Enlivex Dr. Roger Pomerantz et Jason Kolbert de D. Boral. Les données ont démontré des améliorations significatives de la réduction de la douleur et de la fonction chez les patients souffrant d’arthrose du genou modérée à sévère, répondant à un besoin médical non satisfaisant dans une grande population de patients sans thérapies modifiant la maladie actuellement approuvées.
Enlivex Therapeutics (Nasdaq: ENLV) hat ein kommendes KOL-Webinar angekündigt, das von D. Boral Capital ausgerichtet wird und am 30. September 2025 um 10.00 Uhr ET stattfinden wird. Das Webinar konzentriert sich auf das Knie-Osteoarthritis-Programm des Unternehmens und die positiven Phase-IIa-Endergebnisse aus der Allocetra™-Behandlung.
Zu dem Panel gehören angesehene Experten, darunter Professor Ali Mobasheri, Professor Philip Conaghan, Enlivexs Vizepräsident Dr. Roger Pomerantz und Jason Kolbert von D. Boral. Die Daten zeigten signifikante Verbesserungen bei Schmerzlinderung und Funktion bei Patienten mit mittel bis schwerer Kniearthrose, was einen ungedeckten medizinischen Bedarf in einer großen Patientengruppe anspricht, für die derzeit keine zugelassenen krankheitsmodifizierenden Therapien vorhanden sind.
Enlivex Therapeutics (ناسداك: ENLV) أعلنت عن ويبینار KOL القادم من تنظيم D. Boral Capital المقرر عقده في 30 سبتمبر 2025 الساعة 10:00 صباحاً بتوقيت شرق الولايات المتحدة. سيركز الويبينار على برنامج التهاب مفاصل الركبة في الشركة وعلى بيانات إيجابية من المرحلة IIa من علاج Allocetra™.
يضم اللجنة خبراء بارزين منهم الأستاذ علي موشياري، الأستاذ فيليب كونهان، نائب رئيس Enlivex الدكتور روجر بومرانتز، وجيسون كولبرت من D. Boral. أظهرت البيانات تحسناً كبيراً في تقليل الألم وتحسين الوظيفة لدى مرضى التهاب مفاصل الركبة من المعتدل إلى الشديد، ما يعالج حاجة طبية غير مُلبّاة في شريحة كبيرة من المرضى بدون وجود علاجات معدِّلة للمرض معتمدة حاليًا.
Enlivex Therapeutics (纳斯达克：ENLV) 已宣布将举行由 D. Boral Capital 主办的KOL网络研讨会，时间为2025 年 9 月 30 日东部时间上午 10:00。研讨会将聚焦公司膝关节炎计划及其 Allocetra™ 疗法最近的阶段 IIa 主要数据阳性。
小组成员包括知名专家阿里·莫博舍里教授、菲利普·康纳汉教授、Enlivex 副主席 罗杰·鲍默恩策博士，以及 D. Boral 的杰森·科尔伯特。数据表明中重度膝关节炎患者的疼痛减轻和功能改善显著，这在一个规模庞大、尚无获批疾病修饰治疗的患者人群中，填补了未被满足的医学需求。
- None.
- None.
Insights
Enlivex's positive Phase IIa results for Allocetra in knee osteoarthritis represent a potential breakthrough in a large, underserved market.
The upcoming KOL webinar featuring world-renowned osteoarthritis experts signals significant momentum behind Enlivex's Allocetra program. The positive Phase IIa topline data mentioned shows both clinically meaningful and statistically significant improvements in two critical areas: pain reduction and functional improvement for moderate-to-severe knee osteoarthritis patients.
What makes this particularly noteworthy is Enlivex's target population – idiopathic, age-related knee osteoarthritis represents an enormous market with limited treatment options. The CEO's statement about "no disease-modifying therapies currently approved" highlights the substantial unmet need and market opportunity.
The caliber of KOLs participating underscores the scientific community's interest in this approach. Both Professor Mobasheri (former OARSI president) and Professor Conaghan (Director of NIHR Leeds BRC) are heavyweights in osteoarthritis research with over 1,100 scientific publications between them. Their involvement lends significant credibility to the program's potential.
The webinar timing suggests Enlivex is preparing for advanced clinical development, likely Phase IIb/III trials. Macrophage reprogramming represents an innovative mechanism of action in osteoarthritis, targeting underlying inflammatory processes rather than just symptom management. If Allocetra continues showing efficacy in larger trials, it could potentially become a first-in-class disease-modifying therapy for KOA – addressing a major unmet need affecting millions globally.
Nes-Ziona, Israel, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, will participate in a live investor webinar, “Advancing Inflammatory Disease Treatment: Insights & Breakthroughs from Enlivex's Knee Osteoarthritis Program,” hosted by D. Boral Capital on September 30, 2025, at 10:00 AM Eastern Time. The discussion will bring together leading key opinion leaders (KOLs) in musculoskeletal disease, alongside Enlivex’s Vice Chairman and D. Boral’s Research Director.
The September 30 KOL webinar will explore recent breakthroughs in treatment approaches discussing the positive Phase IIa topline data from Enlivex’s Allocetra™ program in moderate-to-severe knee osteoarthritis (KOA) patients. Data demonstrated clinically meaningful and highly statistically significant reduction in pain and improvements in function in idiopathic, age-related knee osteoarthritis patients, a large, underserved population.
Register now to reserve your spot for the webinar:
https://dboralcapital.zoom.us/webinar/register/WN_2S_71t_kQa2KZXj5HMOL7w#/registration
Date/Time: September 30, 2025, at 10:00 AM Eastern Time
Exclusive panel members:
Professor Ali Mobasheri Ph.D – Professor of Musculoskeletal Biology at the University of Oulu, Finland, and former President of the Osteoarthritis Research Society International (OARSI). He also advises the WHO on musculoskeletal health, has published over 400 scientific articles, and is recognized globally for his work in cartilage biology and osteoarthritis biomarkers.
Professor Philip Conaghan, MBBS, PhD, FRACP, FRCP – Consultant Rheumatologist and Director of the NIHR Leeds Biomedical Research Centre. An international leader in osteoarthritis and musculoskeletal imaging, he has authored more than 700 publications and chaired multiple global guideline and trial initiatives.
Dr. Roger Pomerantz, M.D. – Vice Chairman of Enlivex Therapeutics. A physician-scientist and biotech executive with decades of leadership experience, he has guided numerous therapies from early research through late-stage development and commercialization.
Jason Kolbert M.Sc. – Managing Director of Healthcare Research at D. Boral Capital. A veteran Wall Street biotech analyst with over 20 years of experience, he brings a unique perspective shaped by roles in both pharmaceutical development and healthcare equity research.
“We are excited to bring together some of the world’s foremost experts in musculoskeletal disease and clinical development to discuss the significant potential of Allocetra™ to potentially change the treatment paradigm for millions of knee osteoarthritis patients,” said Oren Hershkovitz, Ph.D., CEO of Enlivex Therapeutics. “With no disease-modifying therapies currently approved, the positive Phase IIa data give us strong momentum as we advance toward late-stage clinical development.”
ABOUT ENLIVEX
Enlivex is a clinical stage macrophage reprogramming immunotherapy company developing Allocetra™, a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. Resetting non-homeostatic macrophages into their homeostatic state is critical for immune system rebalancing and resolution of life-threatening and life debilitating conditions. For more information, visit https://enlivex.com/.
Safe Harbor Statement: This press release contains forward-looking statements, which may be identified by words such as “expects,” “plans,” “projects,” “will,” “may,” “anticipates,” “believes,” “should,” “would,” “could,” “intends,” “estimates,” “suggests,” “target,” “has the potential to” and other words of similar meaning, including statements regarding expected cash balances, expected clinical trial results, market opportunities for the results of current clinical studies and preclinical experiments, the effectiveness of, and market opportunities for, ALLOCETRATM programs. All such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that forward-looking statements involve risks and uncertainties that may affect Enlivex’s business and prospects, including the risks that Enlivex may not succeed in generating any revenues or developing any commercial products; that the products in development may fail, may not achieve the expected results or effectiveness and/or may not generate data that would support the approval or marketing of these products for the indications being studied or for other indications; that ongoing studies may not continue to show substantial or any activity; and other risks and uncertainties that may cause results to differ materially from those set forth in the forward-looking statements. The results of clinical trials in humans may produce results that differ significantly from the results of clinical and other trials in animals. The results of early-stage trials may differ significantly from the results of more developed, later-stage trials. The development of any products using the ALLOCETRATM product line could also be affected by a number of other factors, including unexpected safety, efficacy or manufacturing issues, additional time requirements for data analyses and decision making, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing and the impact of patents and other proprietary rights held by competitors and other third parties. In addition to the risk factors described above, investors should consider the economic, competitive, governmental, technological and other factors discussed in Enlivex’s filings with the Securities and Exchange Commission, including in the Company’s most recent Annual Report on Form 20-F filed with the Securities and Exchange Commission. The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements, except as required under applicable law.
ENLIVEX CONTACT
Shachar Shlosberger, CFO
Enlivex Therapeutics, Ltd.
shachar@enlivexpharm.com
INVESTOR RELATIONS CONTACT
Dave Gentry, CEO
RedChip Companies Inc.
1-407-644-4256
ENLV@redchip.com
FAQ
When is Enlivex Therapeutics (ENLV) hosting their KOL webinar on knee osteoarthritis?
What were the results of Enlivex's Phase IIa trial for knee osteoarthritis?
Who are the key speakers at the Enlivex (ENLV) KOL webinar?
How can investors register for the Enlivex Therapeutics webinar?
